Feb 17, 2022
Sandy Macrae Ph.D. is the CEO of Sangamo Therapeutics which has a unique technology called zinc finger. This allows them to find and modify a particular DNA either to delete a faulty gene or to help enhance one that isn't producing enough or turn one down when it's producing too much. While currently focusing on rare diseases like hemophilia, Sangamo is also moving into treating neurodegenerative diseases, multiple sclerosis, inflammatory bowel disease, and kidney transplants with genomic medicine and cell therapy.
Sandy explains, "Sangamo has been at the forefront of genomic medicine for 26 years now, and the world has changed so much and is now embracing genomic medicines as one of the key parts of the tools that we have to address serious diseases."
"I think in the future, there'll be three kinds of medicines. There will be the medicines you take or inject, there'll be the vaccines that prevent disease, and then there'll be genomic medicines that will help solve some of the long problems from our genomic DNA that so many patients struggle with. So I think it's going to be a fundamental core part of what we do. It's important, though, to say these are early days, and every patient that volunteers we are immensely grateful to. We learn from each patient on a daily basis, and it helps us all move these medicines forward."
@SangamoTX #CellTherapy #GeneTherapy #GeneRegulation #ZincFinger #GenomicMedicine #RareDiseases #RareDiseaseMonth
